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Abstract 
Background 
Studies have found an association between proton pump inhibitor (PPI) use and Clostridium 
difficile (C.difficile) infection. The purpose of this study was to determine whether the 
mechanism by which PPIs induce an increased risk of C.difficile infection is supported by the 
same mechanism acting in another cause of achlorhydria, pernicious anaemia. 
Methods 
Using a database of anonymised primary care records between 1990 -2013, we selected 
exposed patients with a diagnosis of pernicious anaemia treated with vitamin B12 therapy. 
Each exposed patient was matched by age, gender, and general practice to up to ten 
controls. Cox regression analysis was used to estimate the hazard ratio (HR) and 95% 
confidence interval (CI) for C.difficile infection with pernicious anaemia, adjusted for 
potential confounders. 
Results 
We identified 45,467 exposed patients matched to 449,635 controls. The crude incidence 
rate of C.difficile infection was 1.85/1000 person-years for the exposed cohort and 1.09/1000 
person-years for controls. Patients with pernicious anaemia had a greater risk of C.difficile 
infection than the controls (adjusted HR 1.57, 95% CI 1.40 -1.76).  
Conclusions 
Pernicious anaemia patients have an increased risk of C.difficile infection. This supports the 
theory that severe hypochlorhydria is the mechanism that increases the risk of C.difficile 
infection in long-term PPI users.
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Key summary 
Summarise the established knowledge on this subject  
• Prior studies have suggested that proton pump inhibitors (PPIs) may cause a risk 
of Clostridium difficile infection. 
• However, it remains unclear if the hypochlorhydria in patients who use PPI on a 
long-term basis is an independent risk factor associated with the increased risk of 
Clostridium difficile infection. 
What are the significant and/or new findings of this study? 
• This study examines the risk of Clostridium difficile infection in patients with 
pernicious anaemia as a surrogate for achlorhydria. 
• Patients with pernicious anaemia exhibited an increased risk of Clostridium 
difficile infection.  
• This suggests that hypochlorhydria in chronic PPI therapy is likely to be the 
underlying mechanism of the increased risk of Clostridium difficile infection.
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Introduction 1 
Clostridium difficile (C. difficile) infection is the most commonly identified cause of 2 
nosocomial and community associated diarrhoea(1–3). Although exposure to antibiotics, 3 
advanced age, and hospitalisation have been recognised as risk factors for C. difficile 4 
infection(3), recent evidence has described C. difficile infection in populations that lack these 5 
traditional risk factors(4,5). Prior studies have suggested that acid-suppressing medication, in 6 
particular proton pump inhibitors (PPI), may cause a risk of C. difficile infection(6–10). A 7 
meta-analysis reported a 65% increase in the incidence of C. difficile infection among PPI 8 
users(11). Although the current observational studies mainly focused on the studying the 9 
association between C. difficile infection and the use of PPIs, the precise mechanism of this 10 
association has remained elusive. 11 
Previous studies have found that PPIs, which act by reducing acid secretion, influence upper 12 
and lower gastrointestinal intestinal microflora and potentially increase a patient’s 13 
susceptibility to enteric infection(10).  Although this mechanism seems widely acceptable, it 14 
has not been conclusively proven and other studies have found that C. difficile spores, which 15 
are the major mode of transmission of  C. difficile infection, are acid resistant (10). In 16 
addition, emerging evidence suggests it is other factors within patients who are prescribed 17 
PPI, rather than the PPI itself that are responsible for the increased risk of other 18 
gastrointestinal infections in those patients(12).  It remains unclear, therefore, if the 19 
reduction in acid secretion (hypochlorhydria) in patients who use PPI on a long-term basis is 20 
an independent risk factor associated with the increased risk of C. difficile infection, or 21 
whether potential confounders, such as comorbidities, can explain the observed associations.  22 
The chronic and persistent hypochlorhydria observed in long-term PPI users is, at least, as 23 
marked as that generally associated with pernicious anaemia patients who also exhibit 24 
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achlorhydria (the absence of hydrochloric acid in the gastric secretions). Herein, the 25 
achlorhydria observed in pernicious anaemia was applied to bridge the gap in understating of 26 
the casual mechanisms that are at play in the relationship between using PPI and C. difficile 27 
infection. The primary objective of the study was to determine whether people with 28 
pernicious anaemia are more likely to develop C. difficile infection than those without it. 29 
Demonstrating this association would provide further evidence that the hypochlorhydria 30 
induced by acid suppressing medications could directly cause the increased risk of C. difficile 31 
infection in patients who receive them. 32 
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Methods  33 
Data source and study design 34 
We performed a matched cohort study using routinely collected electronic healthcare data 35 
from UK primary care practices that were extracted from the Clinical Practice Research 36 
Datalink (CPRD)(13,14). This database consists of anonymised primary care records from 37 
around 681 participating practices, and the data included in it represent around 7% of the UK 38 
population. The data within CPRD includes information on patients’ demographics, clinical 39 
diagnosis, drug prescription, investigation history, and any referral(13). More than half of the 40 
records contained within the CPRD are linked to secondary care data in the Hospital Episode 41 
Statistics (HES) database. The HES data include records of all hospital admissions along with 42 
the primary and secondary diagnosis coded using ICD-10 for each admission, date of 43 
admission, and discharge status(15).    44 
Study population 45 
We identified all individuals with an acceptable registration status within the CPRD from 1990 46 
to 2013 who had at least one year of active registration following the date of current 47 
registration or the date the practice became “up to standard” (UTS)(13) on CPRD, whichever 48 
was the latest. We identified within these a subgroup of patients for whom linked HES data 49 
was available to increase the sensitivity of detecting outcomes by including hospital data. 50 
Within this subgroup we used both CPRD and HES data to define the cases and outcome 51 
events where the first diagnosis recorded in either data source was selected as the event 52 
date. For this subset, the follow-up period was also modified to ensure it was consistent with 53 
the linkage coverage period from 1997 to 2012. 54 
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Identification of exposed and unexposed cohort 55 
From the list of eligible patients, we selected adult patients who had a coded diagnosis of 56 
vitamin B12 deficiency anaemia or pernicious anaemia and who had been prescribed 57 
concurrent vitamin B12 therapy, the current standard of care for this condition. We excluded 58 
patients from the exposed cohort who were receiving vitamin B12 therapy, but had a pre-59 
existing alternative aetiology, such as gastrectomy, intestinal resection, generalised 60 
malabsorption, or PPI use. PPI use was considered to be the indication if the date of the B12 61 
prescriptions fell within the period of continuous use of PPI prior to cohort entry. The start of 62 
follow-up for the exposed group was the date of diagnosis or the first date of UTS 63 
prospective data if the UTS date was later than the date of diagnosis.  64 
Ten unexposed patients for each case were randomly matched for age (within five years), 65 
gender, general practice, and the start date of follow-up with a matched exposed patient. All 66 
patients that met the inclusion criteria for the exposed cohort group, and all those who were 67 
receiving vitamin B12 prescriptions for indications other than pernicious anaemia, were 68 
excluded from the control group. 69 
The end of the follow-up was defined as the date of the first outcome event on record, the 70 
date of the patient’s exit from the database, or the last download from their practice 71 
(whichever was the earliest). Patients were censored if they developed one of the alternative 72 
aetiologies after commencing vitamin B12 therapy. If the patients issued PPI prescription 73 
after the cohort entry and B12 prescription date fell within continuous use of PPI, they were 74 
censored on the date of the PPI prescription. 75 
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Outcome and covariates 76 
We defined C. difficile infection in the CPRD by the presence of a clinical diagnosis of C. 77 
difficile infection codes recorded in the medical record by the general practitioner and/or 78 
positive C. difficile toxin assay. We used information from both primary care and HES data in 79 
the subgroup of patients with available linked data to additional outcomes with an ICD code 80 
(A04.7 for C. difficile colitis). The first C. difficile diagnosis recorded in either data source was 81 
considered to represent the event date.  82 
The following variables were considered as potential confounders: socioeconomic status 83 
(using individual IMD quintiles), co morbidity as measured by the Charlson index(16), 84 
smoking, hospitalisation, and the use of acid-suppressing medication, immunosuppressant 85 
drugs, antibiotics, and corticosteroids. As it is likely that there will be non-random missing 86 
data particularly for smoking, we will model missingness as a separate category. 87 
Statistical analyses 88 
Descriptive analyses were carried out to compare the baseline characteristics between cases 89 
and control groups. A two-sided likelihood ratio chi-square test was used to analyse the 90 
categorical variables. We carried out a multivariable Cox regression analysis to estimate the 91 
hazard ratio (HRs) and 95% confidence interval for the risk of C. difficile infection (first failure) 92 
in the exposed cohort compared to the un-exposed cohort. We checked for violation of the 93 
proportional hazards assumption in these models via log-log plots and Stata’s stph test. 94 
Use of antibiotics(17) and hospitalization(18) were included in the multivariate model as  a 95 
priori, and other potential confounders were entered if they were significantly associated 96 
with the outcome in univariate analysis (P ≤ 0.05), and retained in the final model if their 97 
inclusion altered the apparent effect size of the univariate Cox model by at least 10%. We 98 
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considered drug exposure variables as time-varying covariates (acid suppressing medication, 99 
use of immunosuppressant drugs, antibiotics, and corticosteroids). Specifically, each patient's 100 
follow-up time was first converted into year-long blocks of time, and the drug exposure 101 
status was then determined for each yearly block. Medical comorbidities were measured at 102 
baseline, and categorised using the Charlson index derived from primary care data (19). 103 
All statistical analyses were performed using STATA 12.0 (College Station, TX) 104 
Sensitivity analyses 105 
In order to assess the robustness of our results, we carried out the following sensitivity 106 
analyses. First, to ensure that the results were not altered by any survival bias in cases, we 107 
restricted the analysis to the subgroup of exposed patients who were diagnosed with 108 
pernicious anaemia for the first time with at least one year of follow-up in CPRD within the 109 
study period. In addition to ensure that any inaccuracy in definition of pernicious anaemia did 110 
not cause bias we carried out an analysis restricting the exposed group to patients with both 111 
a specific pernicious anaemia diagnosis code(i.e., excluding patients with vitamin B12 112 
deficiency anaemia due to other causes) and vitamin B12 therapy.  113 
Furthermore, as antibiotic prescriptions are often prescribed for a short term and considered 114 
as markers of illness severity, we modelled the antibiotic use as the number of prescriptions 115 
during the follow-up period in a separate analysis and categorised usage as follows: no 116 
antibiotic use, <4, and 4 or more antibiotic prescriptions to account for the complex changes 117 
in use of the antibiotic as a risk factor in the analysis. 118 
Sample size calculation 119 
An initial feasibility count in CPRD identified 38,842 cases (patients with pernicious anaemia). 120 
Of these, 312 had a record of C. difficile subsequent to pernicious anaemia diagnosis. 121 
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Previous studies have estimated that the odds ratio for C. difficile is above 2(6) in patients 122 
who take PPIs. Using ten controls per case, we expected to achieve 99% power to detect an 123 
effect of this size or larger in those with pernicious anaemia and to achieve >90% power 124 
using HES-linked cases alone.125 
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Results 126 
Study population 127 
We identified 45,467 patients within CPRD who had a diagnosis of vitamin B12 deficiency 128 
anaemia or pernicious anaemia and had received vitamin B12 therapy for at least one year. 129 
To these cases we successfully matched a total of 449,635 unexposed patients on age, 130 
gender, and general practice (Figure 1). The CPRD-HES linked information was available for 131 
24,869 exposed patients and their 246,593 controls. Table 1 presents the characteristics of 132 
the study population at the start of follow-up. The exposed cohort was more likely to have a 133 
higher burden of comorbidity and had used more medication compared to the control group. 134 
Primary analysis 135 
The mean follow-up time was similar in exposed cohort and in the unexposed group (5 years 136 
in both). Overall, the crude incidence rate of C. difficile was higher among patients with a 137 
diagnosis of pernicious anaemia, 1.85 cases per 1000 persons years of follow-up, compared 138 
with matched controls, 1.09 cases per 1000 persons years of follow-up. The unadjusted Cox 139 
regression analysis revealed that the exposed group had an increased risk of C. difficile 140 
infection compared to the controls with a HR of 1.76 (95% CI 1.58 to 1.97). After adjusting for 141 
confounders, the HR for the association between pernicious anaemia and C. difficile infection 142 
decreased to 1.57 (95% CI 1.40 to 1.76). (Table 2). 143 
The adjusted HR for C. difficile infection in the HES subset was similar at 1.67 (05% CI 1.44- 144 
1.94). 145 
Sensitivity analyses:  146 
The analysis of pernicious anaemia patients who had an incident diagnosis of pernicious 147 
anaemia and who were on vitamin B12 therapy yielded similar results to our primary analysis 148 
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(Table 2). The analysis of those patients who had been diagnosed with pernicious anaemia 149 
based only on pernicious anaemia diagnosis codes and B12 injections showed a slightly 150 
higher adjusted HR(1.73 95%CI 1.41 to 2.13). The result of the adjusted analysis in which we 151 
modelled the antibiotic usage as number of prescriptions showed very similar hazard ratio to 152 
our primary analysis (Table 2).153 
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Discussion 154 
In this cohort study, patients with a pernicious anaemia diagnosis had an increased risk of C. 155 
difficile infection. This association persisted when we limited the analysis to a subgroup with 156 
a more restrictive definition of pernicious anaemia diagnosis, or to incident cases. 157 
Limitations and strengths of the study 158 
As our study was conducted using anonymised electronic patient records, we were not able 159 
to confirm the diagnoses of both the exposure and outcome. However, we believe that, 160 
although these individual diagnoses have not been specifically validated in CPRD data, the 161 
numerous previous studies that have validated the information contained in the CPRD(20–162 
22) suggest that errors in the assigned diagnoses are not likely to be common. In addition, 163 
since it is unlikely any such error would be more or less common in either group, any bias 164 
resulting is likely to merely reduce the apparent association observed. Furthermore, we have 165 
attempted to further reassure ourselves in this regard, by insisting on a record of vitamin B12 166 
therapy to define our exposure which should have minimised the risk of misclassification, and 167 
our sensitivity analysis restricted to patients with pernicious anaemia specific diagnosis 168 
codes, where this definition had  been previously used in a study that utilized similar 169 
database(23), further supports our belief that misclassification did not have a major impact 170 
on our results. In addition, this study was limited to the data recorded in our dataset and we 171 
attempted to control for a variety of confounders through applying both matching and 172 
adjustment techniques in the analyses; still, we cannot be certain that there is not residual 173 
confounding by unmeasured factors. However, our results were similar to those previous 174 
studies that have found an association between the use of PPI therapy and C. difficile 175 
infection(6,11). This suggests we think, that given the differences between pernicious 176 
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anaemia patients and PPI using patients, it would be a remarkable coincidence that 177 
confounding alone caused the associations that were observed in both studies. Rather, the 178 
generalisability of the result to a further cause of hypochlorhydria supports the possibility 179 
that the association is causal. 180 
In addition to the limitations outlined above, the data employed in this study had a number 181 
of significant advantages. Firstly, the large number of records within the CPRD gave us an 182 
adequate power to detect rare diseases and their outcomes. Since the data was collected 183 
independently of the research, this should greatly reduce the risk of information bias(13). 184 
Similarly, the selection of all available cases and a random subset of appropriate controls 185 
should mean that our study is free from selection bias. To further assure ourselves of this 186 
with regard to survivorship, we conducted a sensitivity analysis of incident cases. The results 187 
of this analysis were similar to those of the overall analysis. Finally, since the CPRD population 188 
is representative of the general UK population(13),our results are likely to be generalizable to 189 
the UK population or similar populations.  190 
Comparison with previous literature: 191 
The idea that hypochlorhydria might predispose to C. Difficile infection dates back to at least 192 
1982 when Gurian and colleagues reported a case that demonstrated that the killing of the 193 
organism and neutralisation of toxin by gastric juice were pH dependent, and that 194 
hypochlorhydria may increase the susceptibility and severity of enteric infection(24). 195 
Recently, several(6,8,25), but not all(26,27), observational studies supported this idea and  196 
demonstrated a significant elevated risk of C. difficile infection in patients on PPI. Two meta-197 
analyses that combined these observational studies using slightly different methods showed 198 
a significant increase in the incidence of C. difficile infection among patients on PPI therapy 199 
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with an overall risk estimate between 1.65 (95% CI 1.41 - 1.93)(11)  and 1.74(95%CI 1.47-200 
2.85) (28). This caused enough concern that the US Food and Drug Administration (FDA) 201 
issued a drug safety statement that PPIs may be associated with C. difficile infection(29). 202 
To date, no randomised placebo-controlled trials have been conducted to solidify the 203 
causality of this effect because the associated ethical issues and challenges related to the 204 
rarity of the outcome to be studied in such trials entails that conducting such studies is 205 
challenging. Although the reduction in stomach acidity decreases the body’s ability to protect 206 
itself against C. difficile proliferation, as outlined above(10), it is biologically plausible that 207 
users of PPIs are different in many ways to other members of the population; as such, it is not 208 
possible to be confident that all confounding has been corrected in the observational studies 209 
that have been performed to date. The chronic and persistent achlorhydria seen in pernicious 210 
anaemia is at least as marked as that generally associated with long-term PPI use. The 211 
association between pernicious anaemia and C. difficile infection demonstrated in this 212 
research therefore suggests, that severe hypochlorhydria can predispose to C. difficile 213 
infection independent of any confounding present in the prescription of PPIs, and is likely 214 
therefore to be the mechanism for increased C. difficile infection in people who have 215 
received long-term acid-suppression medication. 216 
Conclusion 217 
In this population-based cohort study, patients with pernicious anaemia exhibited an 218 
increased risk of C. difficile infection. The results suggest that hypochlorhydria in chronic PPI 219 
therapy is likely to be the underlying mechanism of the increased risk of C. difficile infection. 220 
This contributes additional data to the evidence that PPI use is a potentially modifiable risk 221 
factor for C. difficile infection. Given the increasing number of patients who are taking long-222 
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term PPIs, this finding suggests that practitioners should be vigilant when prescribing a PPI, 223 
particularly to patients who have other risk factors for developing C. difficile infection. 224 
17 
 
Ethical approval:  This study was approved by the Independent Scientific Advisory Committee (ISAC) 
with CPRD number 15_240R, and 15_240RMn for minor amendment. 
 
Conflict of Interest: FO has received scholarship award from King Saud bin Abdulaziz University for 
Health sciences- Saudi Arabia which sponsors her studies at University Of Nottingham; no support or 
financial relationships with any other organisation for the submitted work, TC and CC were 
independent of the funder and disclose no other conflicts. 
 
Declaration of funding interests: Fatmah Othman has carried out this study as part of her PhD program 
at University of Nottingham. She has received scholarship award from King Saud bin Abdulaziz 
University for Health sciences- Saudi Arabia that sponsors her studies.  
 
Author contributions: Dr.Timothy Card proposed the original idea for the study, planned the study 
design and the analysis, involved in interpretation of results, and revised the paper critically. Fatmah 
Othman helped in planning the analysis and was responsible for conducting the data management, 
statistical analyses, and writing up the first draft of the paper. Dr.Colin Crooks contributed to study 
design and concept, analysis planning, and in interpretation of results as well as to revising the drafts 
of the paper.  
All authors approved the final version. 
 
    
18 
 
References 1 
1.  Blossom DB, McDonald LC. The Challenges Posed by Reemerging Clostridium difficile 2 
Infection. Clin Infect Dis. 2007 Jul 15;45(2):222–7.  3 
2.  Bouza E. Consequences of Clostridium difficile infection: understanding the healthcare 4 
burden. Clin Microbiol Infect. 2012;18:5–12.  5 
3.  Vindigni SM, Surawicz CM. C. difficile Infection: Changing Epidemiology and 6 
Management Paradigms. Clin Transl Gastroenterol. Nature Publishing Group; 2015 Jul 7 
9;6(7):e99.  8 
4.  Deshpande A, Pasupuleti V, Thota P, Pant C, Rolston DDK, Sferra TJ, et al. Community-9 
associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob 10 
Chemother. 2013 Sep;68(9):1951–61.  11 
5.  Gupta A, Khanna S. Community-acquired Clostridium difficile infection: an increasing 12 
public health threat. Infect Drug Resist. 2014;7:63–72.  13 
6.  Dial S, Delaney JAC, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the 14 
risk of community-acquired Clostridium difficile-associated disease. JAMA. American 15 
Medical Association; 2005 Dec 21;294(23):2989–95.  16 
7.  Wilcox MH, Mooney L, Bendall R, Settle CD, Fawley WN. A case-control study of 17 
community-associated Clostridium difficile infection. J Antimicrob Chemother. 2008 18 
Aug;62(2):388–96.  19 
8.  Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M, et al. Iatrogenic 20 
Gastric Acid Suppression and the Risk of Nosocomial Clostridium difficile Infection. 21 
Arch Intern Med. American Medical Association; 2010 May 10;170(9):784.  22 
9.  Linsky A, Gupta K, Lawler E V., Fonda JR, Hermos JA, MS D, et al. Proton Pump 23 
Inhibitors and Risk for Recurrent Clostridium difficile Infection. Arch Intern Med. 24 
American Medical Association; 2010 May 10;170(9):772.  25 
10.  Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and 26 
increased susceptibility to enteric infection. Aliment Pharmacol Ther. 2011 Dec;34(11–27 
12):1269–81.  28 
11.  Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated 29 
diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 30 
2012 Jul;107(7):1001–10.  31 
12.  Brophy S, Jones KH, Rahman MA, Zhou S-M, John A, Atkinson MD, et al. Incidence of 32 
Campylobacter and Salmonella infections following first prescription for PPI: a cohort 33 
study using routine data. Am J Gastroenterol. 2013 Jul;108(7):1094–100.  34 
13.  Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, et al. Data 35 
Resource Profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015 Jun 36 
6;44(3):827–36.  37 
14.  CPRD. The Clinical Practice Research Datalink [Internet]. 2015 [cited 2015 Jun 25]. 38 
Available from: www.cprd.com 39 
15.  HES. Hospital Episode Statistics [Internet]. 2015. Available from: 40 
http://www.hscic.gov.uk/hes 41 
16.  Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying 42 
prognostic comorbidity in longitudinal studies: development and validation. J Chronic 43 
Dis. 1987 Jan;40(5):373–83.  44 
17.  Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the 45 
risk of community-associated Clostridium difficile infection. Antimicrob Agents 46 
19 
 
Chemother. American Society for Microbiology (ASM); 2013 May;57(5):2326–32.  47 
18.  Barbut F, Petit J-C. Epidemiology of Clostridium difficile-associated infections. Clin 48 
Microbiol Infect. Blackwell Science Ltd; 2001 Aug;7(8):405–10.  49 
19.  Crooks CJ, West J, Card TR. A comparison of the recording of comorbidity in primary 50 
and secondary care by using the Charlson Index to predict short-term and long-term 51 
survival in a routine linked data cohort. BMJ Open. 2015 Jan 5;5(6):e007974.  52 
20.  Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General 53 
Practice Research Database: A systematic review. Br J Gen Pract. 2010;60(March):199–54 
206.  55 
21.  Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of 56 
diagnoses in the General Practice Research Database: A systematic review. Br J Clin 57 
Pharmacol. 2010;69:4–14.  58 
22.  Williams T, van Staa T, Puri S, Eaton S. Recent advances in the utility and use of the 59 
General Practice Research Database as an example of a UK Primary Care Data 60 
resource. Ther Adv Drug Saf. 2012 Feb 2;3(2):89–99.  61 
23.  Merriman NA, Putt ME, Metz DC, Yang Y-X. Hip fracture risk in patients with a 62 
diagnosis of pernicious anemia. Gastroenterology. 2010 Apr;138(4):1330–7.  63 
24.  Gurian L, Ward TT, Katon RM. Possible foodborne transmission in a case of 64 
pseudomembranous colitis due to Clostridium difficile: influence of gastrointestinal 65 
secretions on Clostridium difficile infection. Gastroenterology. 1982 Aug;83(2):465–9.  66 
25.  Dial S, Delaney JAC, Schneider V, Suissa S. Proton pump inhibitor use and risk of 67 
community-acquired Clostridium difficile-associated disease defined by prescription 68 
for oral vancomycin therapy. CMAJ. 2006 Sep 26;175(7):745–8.  69 
26.  Lowe DO, Mamdani MM, Kopp A, Low DE, Juurlink DN. Proton Pump Inhibitors and 70 
Hospitalization for Clostridium Difficile--Associated Disease: A Population-Based Study. 71 
Clin Infect Dis. 2006 Nov 15;43(10):1272–6.  72 
27.  Khanna S, Aronson SL, Kammer PP, Baddour LM, Pardi DS. Gastric Acid Suppression 73 
and Outcomes in Clostridium difficile Infection: A Population-Based Study. JMCP. 74 
2012;87(7):636–42.  75 
28.  Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium 76 
difficile Infection With Acid Suppressing Drugs and Antibiotics: Meta-Analysis. Am J 77 
Gastroenterol. Nature Publishing Group; 2012 Jul 24;107(7):1011–9.  78 
29.  The U.S. Food and Drug Administration (FDA). FDA Drug Safety Communication: 79 
Clostridium difficile-associated diarrhea can be associated with stomach acid drugs 80 
known as proton pump inhibitors (PPIs) [Internet]. U.S. Food and Drug Administration 81 
(FDA); 2012 [cited 2016 Jun 22]. Available from: 82 
http://www.fda.gov/Drugs/DrugSafety/ucm290510.htm 83 
 84 
20 
 
Tables: 
Table 1 Demographic and clinical characteristics of the study population included in the 
cohort study by exposure status at cohort entry into the study period, for all CPRD patients 
and for the subset of patients with HES- linked data 
 
HES Hospital Episode Statistics 
* Socioeconomic status is based on Index of multiple deprivation (IMD) and figures are the 
percentage of the patients eligible for inclusion in the linkage to patient level deprivation 
data.  
 
 
 Complete cohort HES linked cohort 
 Total number of patients 
495,102 
Total number of patients 
271,462 
 Unexposed, % Exposed, % Unexposed, % Exposed, % 
characteristic 449,635  45,467  246,593  24,869  
Age (mean SD) 64(17)  65(17)  64(17)  65(17)  
Smoking         
Never smoked 155,877 34 14,152 31 75,439 31 7,035 28 
smoker 122,311 27 12,810 28 63,914 26 6,905 27 
missing 171,447 38 18,505 41 107,240 43 10,929 44 
Index of Multiple 
Deprivation (IMD) 
        
Quintiles*         
1(least deprived) 50,695 20 4,581 18 38,801 20 3,505 17 
2 60,257 23 5,775 22 45,872 23 4,403 22 
3 53,159 21 5,277 20 40,284 20 4,038 20 
4 51,201 20 5,503 21 39,168 20 4,226 21 
5(most deprived) 42,149 16 4,848 19 31,840 16 3,737 19 
Charlson comorbidity 
index score 
        
0 200,730 45 17,029 37 105,860 43 8,619 35 
1-2 122,141 27 12,507 28 67,419 27 6,892 28 
3-4 92,608 21 10,349 23 53,337 22 5,973 24 
>5 34,156 7 5,582 12   19,977 8 3,385 13 
Medications         
Acid suppressing 70,500 16 8,993 20 36,531 15 4,982 20 
Immunosuppressant 18,641 4 2,886 6 6,141 2 971 4 
Corticosteroids 42,257 9 5,617 12 24,013 10 3,206 13 
Antibiotics 133,547 30 15,156 33 70,461 28 8,131 33 
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Table 2: Adjusted and unadjusted hazard ratios and 95% confidence intervals (95% CI) for the association of Clostridium Difficile infection with pernicious 
anaemia. 
CPRD, Clinical Practice Research Datalink, HES, Hospital Episode Statistics data, HR, Hazard ratio,  CI, confidence interval 
a Model adjusted for comorbidity index, hospitalization, and use of antibiotics, acid suppression therapy, and immunosuppressant drugs. 
b Model adjusted for comorbidity index, hospitalization, and use of antibiotics ( as number of prescriptions), acid suppression therapy, and immunosuppressant 
drugs 
  
Unexposed cohort Exposed cohort HR 
 
 
Study 
Population  
Exposure definition No. of 
patients 
Clostridiu
m Difficile 
infection 
event  
(%) 
Rate of 
Clostridium 
Difficile 
per 1,000 
person years 
(95%CI) 
No. of 
patients 
Clostridium 
Difficile 
infection 
event  
(%) 
Rate of 
Clostridium 
Difficile 
per 1,000 
person years 
(95%CI) 
unadjusted 
HR 
(95% CI) 
adjusted HRa 
(95% CI) 
adjusted HRb 
(95% CI) 
CPRD patients 
        
 
The main analysis  449,635 2,492(0.5) 1.09 
(1.05 to 1.13) 
45,467 429(0.9) 1.85 
(1.69 to 2.04) 
1.76 
(1.58 to 1.96) 
1.57  
(1.40 to 1.76) 
1.60  
(1.43 to 1.80) 
Sensitivity  
analysis  
Newly diagnosed cases 
with at least 1 year of 
follow-up in CPRD 
282,830 1,685(0.5) 1.34 
(1.28 to 1.49) 
28,590 278(0.9) 2.21 
(1.96 to 2.49) 
1.68 
(1.47 to 1.92) 
1.43 
(1.24 to 1.64) 
1.44  
(1.25 to 1.66) 
 
Cases in the exposed 
cohort with pernicious 
anaemia diagnosis 
code only  
165,987 855(0.5) 0.88 
(0.83 to 0.94) 
16,735 141(0.8) 1.44 
(1.22 to 1.70) 
1.80 
(1.48 to 2.18) 
1.73 
(1.41 to 2.13) 
1.77 
(1.44 to 2.18) 
 
CPRD_HES linked patients 
       
 
The main analysis  246,593 1,453(0.5) 1.30 
(1.24 to 1.37) 
24,869  272 (1.2) 2.44 
(2.16 to 2.74) 
1.97  
(1.72 to 2.26) 
1.67 
(1.44 to 1.94) 
1.58 
(1.36 to 1.84) 
Sensitivity  
analysis 
Newly diagnosed cases 
with at least 1 year of 
follow-up in CPRD 
154,678 899 (0.5) 1.58 
(1.48 to 1.68) 
15,611 175(1.1) 3.08 
(2.65 to 3.57) 
2.03 
(1.71 to 2.40) 
1.64 
(1.36 to 1.98) 
1.55 
(1.29 to 1.87) 
 
Cases in the exposed 
cohort with pernicious 
anaemia diagnosis 
code only  
80,324 496 (0.6) 1.16 
(1.06 to 1.27) 
8,069 85(1.1) 1.98 
(1.60 to 2.44) 
1.80 
(1.40 to 2.30) 
1.59  
(1.21 to 2.09) 
1.56 
(1.18 to 2.05) 
